Core Viewpoint - Yuheng Pharmaceutical (002437) announced that its wholly-owned subsidiary, Pude Pharmaceutical, received approval from the National Medical Products Administration for the injection of multiple vitamins (12) [1] Group 1: Product Approval and Market Potential - The injection of multiple vitamins (12) has passed the consistency evaluation of generic drug quality and efficacy [1] - The product is intended for adult and pediatric patients aged 11 and above, with projected sales in urban public hospitals and county-level public medical institutions in China amounting to 1.916 billion yuan in 2024 [1] Group 2: R&D Investment - Pude Pharmaceutical has invested approximately 3.6706 million yuan in the consistency evaluation work for this product [1]

Group 1: Company Performance and Financials - The company's revenue has significantly declined compared to 2018 and 2019, primarily due to the sale of Auno (China) Pharmaceutical Co., Ltd. in late 2019, which is no longer included in the consolidated financial statements [2] - In Q1 2025, the company's revenue decreased by 7.06% year-on-year, while net profit attributable to shareholders increased by 15.24% [6] - The company expects stable or slightly declining revenue for 2025, with continued growth in operating performance [6] Group 2: Product and Market Insights - Major products have been subjected to centralized procurement, with significant sales growth expected for the injection of multi-vitamins (over 40% in 2024) [3] - The company has a diverse product portfolio, including traditional Chinese medicine and various injectable products, with a focus on maintaining stable growth in existing products [6][10] - The company is primarily engaged in generic drug business, with plans to explore differentiated generics and high-barrier generics in the short term [10] Group 3: Corporate Structure and Shareholder Information - The company has undergone multiple acquisitions, with goodwill amounting to 369 million yuan as of the end of 2024, with no impairment risks identified [5] - Major shareholders include Shen Zhenyu and others, holding over 20% of total shares, with Shen Zhenyu's stake at approximately 10% as of Q1 2025 [13] - The company completed a share repurchase plan in March 2025, utilizing approximately 80 million yuan to buy back 32.31 million shares, representing 1.42% of the total share capital [11]

哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2025-055 哈尔滨誉衡药业股份有限公司 关于全资下属公司与卫材（中国）药业有限公司 就甲钴胺注射液（商品名：弥可保）签订市场推广服务协议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、协议签署时间及主要内容 （一）协议签署时间 2025 年 6 月 1 日，哈尔滨誉衡药业股份有限公司（以下简称"公司"）全资 下属公司天津誉衡博达科技有限公司（以下简称"天津博达"）与卫材（中国） 药业有限公司（以下简称"卫材中国药业"）就"甲钴胺注射液"（商品名：弥 可保）签订《市场推广服务协议》（以下简称"协议"）。 （二）协议主要内容 1、卫材中国药业授权天津博达在中国大陆地区（不包括香港特别行政区、 澳门特别行政区和台湾地区）独家推广甲钴胺注射液（商品名：弥可保），授权 期限自 2025 年 6 月 1 日起至协议有效期届满之日终止。 2、天津博达负责提供该产品在上述区域的市场推广服务和其他相关服务。 3、卫材中国药业将按照协议约定向天津博达支付相应的市场推广服务费。 （五 ...

誉衡药业（002437）公告，2025年6月1日，全资下属公司天津誉衡博达科技有限公司与卫材(中国)药业 有限公司就甲钴胺注射液(商品名：弥可保)签订《市场推广服务协议》。协议有效期至2026年3月31 日，到期后若满足条件可自动续约两年至2028年3月31日。卫材中国药业授权天津博达在中国大陆地区 独家推广甲钴胺注射液，天津博达负责市场推广服务及其他相关服务。卫材中国药业将支付市场推广服 务费。此次合作将丰富誉衡药业产品管线，增加营业收入及利润。 ...

Group 1 - Huapei Power received a project intention letter from a domestic new energy vehicle company for a thermal management system PTC water heater, with an estimated sales amount of approximately 9 million yuan over a 5-year lifecycle starting from 2026 [1] - Antu Biotech obtained medical device registration certificates for products including "Cytomegalovirus IgM Antibody Test Kit" [1][2] - Yihong Technology adjusted the upper limit of its share repurchase price to 65.04 yuan per share, with a total repurchase amount of 6.9583 million yuan for 198,000 shares [2] Group 2 - Aihui Long received a medical device registration certificate for the Hepatitis B virus core antibody detection kit, valid until May 28, 2030 [2][3] - Quanxin Co. plans to engage in commodity futures hedging to mitigate raw material price fluctuations, with a maximum guarantee amount of 8 million yuan [3] - Jiahua Intelligent plans to lease idle assets in Dongguan for a total rental amount of approximately 6.3193 million yuan over 6 years [3] Group 3 - Qianjiang Biochemical announced the resignation of its chairman and a director, with a new chairman to be elected [4][5] - Aerospace Morning Light was suspended from participating in military procurement activities due to violations, with internal investigations underway [6] - Guang'an Aizhong intends to establish a fund with a total scale of 70.7 million yuan, focusing on distributed wind and solar power generation [7] Group 4 - Zhejiang Medicine plans to use up to 1 billion yuan of idle funds for entrusted wealth management, with a maximum investment period of 12 months [10] - Hengrui Medicine's subsidiary received approval for clinical trials of HRS9531 injection, aimed at treating type 2 diabetes patients [11] - Taiji Co. announced the purchase of 10 million yuan in wealth management products, with a minimum holding period of 6 months [12] Group 5 - Hong Kong-listed company Huichuang Pharmaceutical received approval for the clinical trial of a spray for treating primary premature ejaculation [26][27] - Haichuang Pharmaceutical's new drug application for a prostate cancer treatment was approved by the National Medical Products Administration [28] - Zhuhai Guanyu was selected as a designated supplier for low-voltage lithium batteries by SAIC Volkswagen [29] Group 6 - Huayi Technology opened a tax refund service for overseas travelers, enhancing its retail offerings [32] - Baobian Electric plans to transfer 90% of its subsidiary's shares for 137 million yuan [33] - Yiwei Communication intends to invest 100 million yuan to establish a wholly-owned subsidiary to enhance its strategic layout [34]

证券代码：002437 证券简称：誉衡药业 公告编号：2025-054 哈尔滨誉衡药业股份有限公司 哈尔滨誉衡药业股份有限公司（以下简称"公司"）副总经理李润宝先生、 副总经理王小航先生及董事、副总经理、董事会秘书刘月寅女士保证信息披露的 内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 润宝先生计划自本公告披露之日起 15 个交易日后的三个月内以集中竞价方式减 持公司股份 587,500 股（占公司股份总数的 0.0262%）。 小航先生计划自本公告披露之日起 15 个交易日后的三个月内以集中竞价方式减 持公司股份 587,500 股（占公司股份总数的 0.0262%）。 经理、董事会秘书刘月寅女士计划自本公告披露之日起 15 个交易日后的三个月 内以集中竞价方式减持公司股份 259,619 股（占公司股份总数的 0.0116%）。 公司于 2025 年 5 月 29 日收到副总经理李润宝先生、副总经理王小航先生及 董事、副总经理、董事会秘书刘月寅女士出具的《股份减持计划告知函》。现将 有关情况公告如下： 一、拟减持股 ...

哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2025-054 哈尔滨誉衡药业股份有限公司 关于公司部分董事及高级管理人员减持股份的预披露公告 哈尔滨誉衡药业股份有限公司（以下简称"公司"）副总经理李润宝先生、 副总经理王小航先生及董事、副总经理、董事会秘书刘月寅女士保证信息披露的 内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、持有公司股份 2,350,000 股（占公司总股本比例 0.1046%）的副总经理李 润宝先生计划自本公告披露之日起 15 个交易日后的三个月内以集中竞价方式减 持公司股份 587,500 股（占公司股份总数的 0.0262%）。 2、持有公司股份 2,350,000 股（占公司总股本比例 0.1046%）的副总经理王 小航先生计划自本公告披露之日起 15 个交易日后的三个月内以集中竞价方式减 持公司股份 587,500 股（占公司股份总数的 0.0262%）。 注：如计划减持期间有送股、资本公积金转增股本、配股等除权除息事项，减持股份数 量将相应进行调 ...

誉衡药业（002437）公告，副总经理李润宝、副总经理王小航及董事、副总经理、董事会秘书刘月寅计 划自公告披露之日起15个交易日后的三个月内，通过集中竞价方式减持公司股份。李润宝和王小航分别 拟减持58.75万股，各占公司总股本的0.0262%；刘月寅拟减持25.96万股，占公司总股本的0.0116%。减 持原因是个人资金需求，减持价格将按市场价格确定。 ...

Market Overview - The Shanghai Composite Index fell by 0.18% on May 27, with 13 industries experiencing gains, led by textiles and apparel (up 1.30%) and the pharmaceutical and biotechnology sector (up 0.97) [1] - The net outflow of capital from the two markets was 19.519 billion yuan, with 8 industries seeing net inflows, primarily in the food and beverage sector, which had a net inflow of 1.006 billion yuan [1] Pharmaceutical and Biotechnology Sector - The pharmaceutical and biotechnology sector rose by 0.97%, with a net inflow of 650 million yuan, and out of 476 stocks in this sector, 372 stocks increased in value, while 94 stocks declined [2] - The top three stocks with the highest net inflow were Longshen Rongfa (1.33 billion yuan), Yuheng Pharmaceutical (1.27 billion yuan), and WuXi AppTec (1.21 billion yuan) [2] - The sector also had notable outflows, with the top three stocks experiencing the largest net outflows being Yixin Pharmacy (-845.979 million yuan), Huadong Medicine (-829.898 million yuan), and Heng Rui Medicine (-752.640 million yuan) [4] Capital Flow in Pharmaceutical Sector - The top gainers in the pharmaceutical sector included Longshen Rongfa (up 11.29%), Yuheng Pharmaceutical (up 9.89%), and WuXi AppTec (up 0.86%) [2] - Conversely, the stocks with the largest capital outflows included Yixin Pharmacy (down 5.20%), Huadong Medicine (up 0.38%), and Heng Rui Medicine (up 0.13%) [4]

Group 1 - Guangdian Electric's wholly-owned subsidiary plans to sell 5.91% stake in Shanghai Winshun Electric Technology Co., Ltd. to Yapp Automotive Parts Co., Ltd. for 62.63 million yuan, aiming to optimize asset structure [1] - Anhui Natural Gas received approval for the registration of 500 million yuan short-term financing bonds and 600 million yuan medium-term notes, valid for two years [1] - Kirin Security received government subsidies totaling 6.48 million yuan, which are related to revenue [2] Group 2 - Junshi Biosciences received approval for two new indications for its self-developed drug, Oncorhynchus monoclonal antibody injection, targeting adult patients with heterozygous familial hypercholesterolemia and non-familial hypercholesterolemia [3] - China Resources Double Crane's subsidiary passed GMP compliance inspection for small and large volume injection production lines [4] - Nanjing Public Utilities' board approved the absorption and merger of its wholly-owned subsidiary, Nanjing Jinguang Industry Co., Ltd. [7] Group 3 - Boya Bio received drug registration certificate for human immunoglobulin (pH4) in the Dominican Republic, valid until August 12, 2029 [8] - Jizhi Co. announced that its controlling shareholder and actual controller committed not to reduce their shareholdings until December 31, 2025 [9] - Yuhua Tian won a bid for the integrated urban management project in Lanzhou City, with a total service subsidy of 353 million yuan [10] Group 4 - Anke Rui obtained five invention patent certificates related to various energy management and control technologies [11] - Kebo Da's wholly-owned subsidiary plans to acquire 100% of Czech IMI Company for approximately 9.43 million euros to enhance global production layout [13] - Yantian Port announced a cash dividend of 1.30 yuan per 10 shares, totaling 676 million yuan [14] Group 5 - Huawang Technology plans to distribute a cash dividend of 0.45 yuan per share and a capital reserve increase of 0.20 shares per share [15] - Kabe Yi established a wholly-owned subsidiary in Japan to enhance its business layout [16] - Dongcheng Pharmaceutical's subsidiary received approval for the marketing of sodium fluoride injection, a PET radiopharmaceutical [18] Group 6 - Huaxin New Materials' subsidiary received two utility model patent certificates for innovative devices [19] - Lingang Steel's new 2290 cubic meter blast furnace has been successfully put into operation [21] - Xinlitai received drug registration certificate for Sacubitril/Valsartan tablets, the first of its kind in China [23] Group 7 - Aike Co.'s subsidiary received project designation notices from multiple clients for electric drive platform components [25] - Tonghe Pharmaceutical received drug registration certificate for Apixaban in South Korea [26] - Junting Hotel signed a cooperation agreement with Choice Hotels for exclusive brand usage in mainland China [28] Group 8 - Guangdong Hongtu plans to establish a wholly-owned subsidiary in Zhengzhou to enhance market layout [30] - Yuheng Pharmaceutical signed a joint promotion agreement for Pemafibrate tablets with Xinghe Pharmaceutical [31] - Chongqing Steel terminated the absorption and merger of its wholly-owned subsidiary, citing strategic advantages of independent operation [33] Group 9 - Jihong Co. announced the listing of its H-shares on the Hong Kong Stock Exchange [34] - Deshi Co. announced plans for shareholders to reduce their holdings by up to 0.3% [36] - Xinhai Medical's subsidiary received medical device registration for a dialysis fluid filter [42]